BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Siliq (brodalumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Siliq (brodalumab)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06673329-93@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Siliq (brodalumab): Phase 1 readout est. (NCT06673329)
DESCRIPTION:Siliq (brodalumab)\, phase 1.\nStudy: Brodalumab in the Treatme
 nt of Immune-Related Adverse Events\nEstimated primary completion: May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/brodalumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06673329
URL:https://assetmemo.bio/drug/brodalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03240809-93@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Siliq (brodalumab): Phase 4 readout est. (NCT03240809)
DESCRIPTION:Siliq (brodalumab)\, phase 4\, Psoriasis.\nStudy: An Open-label
 \, Single-dose Study to Evaluate Safety\, Tolerability\, and Pharmacokinet
 ics of Brodalumab in Pediatric Subjects\nEstimated primary completion: Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brodaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 240809
URL:https://assetmemo.bio/drug/brodalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
